Clinical trials in neonates and children: Report of the pulmonary hypertension academic research consortium pediatric advisory committee

Pulmonary Circulation

Volumn 3, Issue 1, 2013, Pages 252-266

  Adatia, Ian ^a   Haworth, Sheila G ^b   Wegner, Max ^c   Barst, Robyn J ^d   Ivy, Dunbar ^e   Stenmark, Kurt R ^e   Karkowsky, Abraham ^f   Rosenzweig, Erika ^d   Aguilar, Christopher ^g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BAYER AG   (Germany)

^d Department of Medicine   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Federal Drug Agency   (United States)

^g GILEAD SCIENCES   (United States)

Author keywords

Drug toxicity; Pediatrics; Pulmonary arterial hypertension; Pulmonary hypertension with increased pulmonary vascular resistance; Pulmonary vascular disease

Indexed keywords

EID: 84901479685     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.109931     Document Type: Article

References (86)

1. Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart (British Cardiac Society) 2010;96:1401-6.
2. van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, et al. Pediatric Pulmonary Hypertension in the Netherlands. Epidemiology and Characterization During the Period 1991 to 2005. Circulation 2011;124:1755-64.
3. Scherrer U, Rimoldi SF, Rexhaj E, Stuber T, Duplain H, Garcin S, et al. Systemic and pulmonary vascular dysfunction in children conceived by assisted reproductive technologies. Circulation 2012;125:1890-6.
4. Reid LM. Lung growth in health and disease. Br J Dis Chest 1984;78:113-34.
5. de Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 2011;7:935-48.
6. Laer S, Meibohm B. Study design and simulation approach. Handb Exp Pharmacol 2011;205:125-48.
7. Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant.A physiologic explanation of its toxicity when given in excessive doses. N Engl J Med 1960;262:787-94.
8. Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD. Clinical safety, pharmacokinetics and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol 2013;48:27-34.
9. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012;125:324-34.
10. Rose K, Della Pasqua O. Development of paediatric medicines: Concepts and principles. Handb Exp Pharmacol 2011;205:111-24.
11. Mestan KK, Marks JD, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 2005;353:23-32.
12. de Vries MC, Wit JM, Engberts DP, Kaspers GJ, van Leeuwen E. Pediatric oncologists’ attitudes towards involving adolescents in decision-making concerning research participation. Pediatr Blood Cancer 2010;55:123-8.
13. UNICEF. State of the world’s children main report 2011; 2011.
14. Nor Aripin KN, Sammons HM, Choonara I. Published pediatric randomized drug trials in developing countries, 1996-2002. Paediatr Drugs 2010;12:99-103.
15. McRorie TI, Lynn AM, Nespeca MK, Opheim KE, Slattery JT. The maturation of morphine clearance and metabolism. Am J Dis Child (1960) 1992;146:972-6.
16. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003;349:2099-107.
17. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PJ, Merrill RJ, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006;355:343-53.
18. Robertson CM, Tyebkhan JM, Peliowski A, Etches PC, Cheung PY. Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure. Acta Paediatr 2006;95:214-23.
19. Robertson CM, Alton GY, Bork KT, Joffe AR, Tawfik GC, Sauve RS, et al. Bilateral sensory permanent hearing loss after palliative hypoplastic left heart syndrome operation. Ann Thorac Surg 2012;93:1248-53.
20. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: Preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012;97:416-25.
21. Laron Z. Growth hormone therapy: Emerging dilemmas. Pediatr Endocrinol Rev 2011;8:364-73.
22. Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 2011;1:286-98.
23. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart (British Cardiac Society) 2009;95:312-7.
24. Barst RJ, McGoon DC, Elliot CG, Foreman AJ, Miller DP, Ivy DD. Survival in Childhood Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management. Circulation 2012;125:113-22.
25. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: A registry study. Lancet 2012;379:537-46.
26. Fraisse A, Jais X, Schleich JM, di Filippo S, Maragnes P, Beghetti M, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010;103:66-74.
27. Fasnacht MS, Tolsa JF, Beghetti M. The Swiss registry for pulmonary arterial hypertension: The paediatric experience. Swiss Med Wkly 2007;137:510-3.
28. Offringa M, van der Lee H. Small sample approach and statistical and epidemiological aspects. Handb Exp Pharmacol 2011;205:181-202.
29. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med 2011;8:161-73.
30. Huber AM, Tomlinson GA, Koren G, Feldman BM. Amitriptyline to relieve pain in juvenile idiopathic arthritis: A pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials. J Rheumatol 2007;34:1125-32.
31. Nikles CJ, Mitchell GK, Del Mar CB, Clavarino A, McNairn N. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder. Pediatr 2006;117:2040-6.
32. Suri R, Metcalfe C, Wallis C, Bush A. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol 2004;37:305-10.
33. EMA Guideline General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products, EMA guideline.
34. Gobburu JV. How to double success rate of pediatric trials? US Food and Drug Administration, Office of Clinical Pharmacology, Silver Spring, MD 2010.
35. Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005;59:674-6.
36. Thomson SA, Tuleu C, Wong IC, Keady S, Pitt KG, Sutcliffe AG. Minitablets: New modality to deliver medicines to preschool-aged children. Pediatr 2009;123:e235-8.
37. Breitkreutz J. Novel drug formulations for children. In: World Pharma. Copenhagen; 2010. Available from: http://www.worldpharma2010.org/ powerpoints.php
38. Whittaker A, Currie AE, Turner MA, Field DJ, Mulla H, Pandya HC. Toxic additives in medication for preterm infants. Arch Dis Child Fetal Neonatal Ed 2009;94:F236-40.
39. Glasgow AM, Boeckx RL, Miller MK, MacDonald MG, August GP, Goodman SI. Hyperosmolality in small infants due to propylene glycol. Pediatr 1983;72:353-5.
40. Lammers AE, Adatia I, Cerro MJ, Diaz G, Freudenthal AH, Freudenthal F, et al. Functional classification of pulmonary hypertension in children: Report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ 2011;1:280-5.
41. Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, et al. Six-minute walk test in children and adolescents. J Pediatr 2007;150:395-9, 9 e1-2.
42. Lammers AE, Hislop AA, Flynn Y, Haworth SG. The 6-minute walk test: Normal values for children of 4-11 years of age. Arch Dis Child 2008;93:464-8.
43. Li AM, Yin J, Au JT, So HK, Tsang T, Wong E, et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med 2007;176:174-80.
44. Nixon PA, Joswiak ML, Fricker FJ. A six-minute walk for assessing exercise tolerance in severely ill children. J Pediatr 1996;129:362-6.
45. Eston RG, Rowlands AV, Ingledew DK. Validity of heart rate, pedometry and accelerometry for predicting the energy cost of children’s activities. J Appl Physiol 1998;84:362-71.
46. Schwaiblmair M, Faul C, von Scheidt W, Berghaus T. Ventilatory efficiency testing as prognostic value in patients with pulmonary hypertension. BMC Pulm Med 2012;12:23.
47. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84.
48. Humpl T, Reyes JT, Erickson S, Armano R, Holtby H, Adatia I. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease. Cardiol Young 2011;21:187-93.
49. Briefing information for cardiovascular and renal drugs advisory committee meeting Use of ΔPVRI for dosing recommendations of adult-approved drugs in pediatric PAH patients. In: Research USFDA Advisory Committee meeting 2010 July 29th.
50. Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR. Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth 2007;98:657-61.
51. Carmosino MJ, Friesen RH, Doran A, Ivy DD. Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. Anesth Analg 2007;104:521-7.
52. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004;110:660-5.
53. Galiè N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet 2008;371:2093-100.
54. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-63.
55. Mullen MP, Andrus J, Labella MH, Forbes P, Rao S, Harris JE, et al. Quality of life and parental functioning in pediatric pulmonary hypertension. Chest 2012.
56. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: Reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001;39:800-12.
57. Streisand R, Braniecki S, Tercyak KP, Kazak AE. Childhood illness-related parenting stress: The pediatric inventory for parents. J Pediatr Psychol 2001;26:155-62.
58. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: An introductory report. Psychol Med 1983;13:595-605.
59. Folkman S, Lazarus RS, Gruen RJ, DeLongis A. Appraisal, coping, health status and psychological symptoms. J Pers Soc Psychol 1986;50:571-9.
60. Association AP. Diagnostic and Statistical Manual of Mental Disorders (Text Revision). 4th ed: USA: American Psychiatric Publishing, Inc; 2000.
61. Gemke RJ, Bonsel GJ. Reliability and validity of a comprehensive health status measure in a heterogeneous population of children admitted to intensive care. J Clin Epidemiol 1996;49:327-33.
62. Robertson CM, Watt JM, Joffe AR, Murphy DB, Nagy JM, McLean DE, et al. Childhood morbidity after severe traumatic brain injury: Increased detection with the Multiattribute Health Status Classification. Pediatr Crit Care Med 2001;2:145-50.
63. Shih CY, Sapru A, Oishi P, Azakie A, Karl TR, Harmon C, et al. Alterations in plasma B-type natriuretic peptide levels after repair of congenital heart defects: A potential perioperative marker. J Thorac Cardiovasc Surg 2006;131:632-8.
64. Chikovani O, Hsu JH, Keller R, Karl TR, Azakie A, Adatia I, et al. B-type natriuretic peptide levels predict outcomes for children on extracorporeal life support after cardiac surgery. J Thorac Cardiovasc Surg 2007;134:1179-87.
65. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2009;135:21-6.
66. Takatsuki S, Wagner BD, Ivy DD. B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. Congenit Heart Dis 2012;7:259-67.
67. Vijlbrief DC, Benders MJ, Kemperman H, van Bel F, de Vries WB. B-type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension. J Pediatr 2012;160:111-5 e1.
68. Yeager ME, Colvin KL, Everett AD, Stenmark KR, Ivy DD. Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics Clin Appl 2012;6:257-67.
69. Yeager ME, Nguyen CM, Belchenko DD, Colvin KL, Takatsuki S, Ivy DD, et al. Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J 2012;39:104-11.
70. Levy M, Maurey C, Celermajer DS, Vouhe PR, Danel C, Bonnet D, et al. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 2007;49:803-10.
71. Smadja DM, Gaussem P, Mauge L, Israel-Biet D, Dignat-George F, Peyrard S, et al. Circulating endothelial cells: A new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009;119:374-81.
72. Gan CT, Lankhaar JW, Westerhof N, Marcus JT, Becker A, Twisk JW, et al. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 2007;132:1906-12.
73. Hunter KS, Lee PF, Lanning CJ, Ivy DD, Kirby KS, Claussen LR, et al. Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. Am Heart J 2008;155:166-74.
74. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006;47:799-803.
75. Hunter KS, Feinstein JA, Ivy DD, Shandas R. Computational Simulation of the Pulmonary Arteries and its Role in the Study of Pediatric Pulmonary Hypertension. Prog Pediatr Cardiol 2010;30:63-9.
76. Hunter KS, Lee PF, Lanning CJ, Ivy DD, Kirby KS, Claussen LR, et al. Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. Am Heart J 2008;155:166-74.
77. Sajan I, Manlhiot C, Reyes J, McCrindle BW, Humpl T, Friedberg MK. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity and survival. Am Heart J 2011;162:562-8.
78. Hunter KS, Lammers SR, Shandas R. Pulmonary Vascular Stiffness: Measurement, Modeling and Implications in Normal and Hypertensive Pulmonary Circulations. In: Comprehensive Physiology; 2011:1413-35.
79. Rodes-Cabau J, Domingo E, Roman A, Majo J, Lara B, Padilla F, et al. Intravascular ultrasound of the elastic pulmonary arteries: a new approach for the evaluation of primary pulmonary hypertension. Heart (British Cardiac Society) 2003;89:311-5.
80. Li M, Scott DE, Shandas R, Stenmark KR, Tan W. High pulsatility flow induces adhesion molecule and cytokine mRNA expression in distal pulmonary artery endothelial cells. Ann Biomed Engg 2009;37:1082-92.
81. Li M, Stenmark KR, Shandas R, Tan W. Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors. J Vasc Res 2009;46:561-71.
82. Robertson CM, Sauve RS, Joffe AR, Alton GY, Moddemann DM, Blakley PM, et al. The registry and follow-up of complex pediatric therapies program of Western Canada: A mechanism for service, audit and research after life-saving therapies for young children. Cardiol Res Pract 2011;2011:1-11.
83. Klassen TP, Hartling L, Hamm M, van der Lee JH, Ursum J, Offringa M. StaR Child Health: An initiative for RCTs in children. Lancet 2009;374:1310-2.
84. Savendahl L, Maes M, Albertsson-Wikland K, Borgstrom B, Carel JC, Henrard S, et al. Long-term mortality and causes of death in isolated GHD, ISS and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands and Sweden: Preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012; 97:E213-7.
85. del Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 2011;1:286-98
86. William S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. PK-Sim: A physiologically based pharmacokinetic ‘whole-body’ model. Biosilico 2003;1:121-4.